{"id":"ir-cd-ld","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Motor fluctuations"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Hallucinations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain to replace depleted neurotransmitter levels in Parkinson's disease. Carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine outside the central nervous system, allowing more levodopa to reach the brain. The immediate-release formulation aims to provide rapid symptom relief compared to extended-release alternatives.","oneSentence":"IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:08.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease motor symptoms"}]},"trialDetails":[{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT03007888","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2016-11-14","conditions":"Advanced Parkinson's Disease","enrollment":28},{"nctId":"NCT00974974","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-09","conditions":"Parkinson's Disease","enrollment":471},{"nctId":"NCT00869791","phase":"PHASE2","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2008-11","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01411137","phase":"PHASE3","title":"Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2011-08","conditions":"Parkinson's Disease","enrollment":43},{"nctId":"NCT02271503","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2015-11","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00253084","phase":"PHASE2","title":"Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT01515410","phase":"PHASE2","title":"Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations","status":"COMPLETED","sponsor":"Depomed","startDate":"2012-01","conditions":"Parkinson's Disease, Motor Fluctuations","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["immediate-release carbidopa-levodopa","Generic for Sinemet tablets"],"phase":"phase_3","status":"active","brandName":"IR CD-LD","genericName":"IR CD-LD","companyName":"Impax Laboratories, LLC","companyId":"impax-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control. Used for Parkinson's disease motor symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}